- Research article
- Open Access
Protective role of all-trans retinoic acid (ATRA) against hypoxia-induced malignant potential of non-invasive breast tumor derived cells
BMC Cancer volume 18, Article number: 1194 (2018)
The presence of hypoxic areas is common in all breast lesions but no data clearly correlate low oxygenation with the acquisition of malignant features by non-invasive cells, particularly by cells from ductal carcinoma in situ (DCIS), the most frequently diagnosed tumor in women.
By using a DCIS-derived cell line, we evaluated the effects of low oxygen availability on malignant features of non-invasive breast tumor cells and the possible role of all-trans retinoic acid (ATRA), a well-known anti-leukemic drug, in counteracting the effects of hypoxia. The involvement of the β2 isoform of PI-PLC (PLC-β2), an ATRA target in myeloid leukemia cells, was also investigated by specific modulation of the protein expression.
We demonstrated that moderate hypoxia is sufficient to induce, in DCIS-derived cells, motility, epithelial-to-mesenchymal transition (EMT) and expression of the stem cell marker CD133, indicative of their increased malignant potential.
Administration of ATRA supports the epithelial-like phenotype of DCIS-derived cells cultured under hypoxia and keeps down the number of CD133 positive cells, abrogating almost completely the effects of poor oxygenation. We also found that the mechanisms triggered by ATRA in non-invasive breast tumor cells cultured under hypoxia is in part mediated by PLC-β2, responsible to counteract the effects of low oxygen availability on CD133 levels.
Overall, we assigned to hypoxia a role in increasing the malignant potential of DCIS-derived cells and we identified in ATRA, currently used in treatment of acute promyelocytic leukemia (APL), an agonist potentially useful in preventing malignant progression of non-invasive breast lesions showing hypoxic areas.
Hypoxia is defined as a reduced oxygen availability and solid tumors, including breast cancer, often contain hypoxic regions because of their rapid and uncontrollable cell proliferation combined with a structurally and functionally abnormal vasculature . Low oxygen availability generates a hostile microenvironment in which tumor cells activate adjustment mechanisms in order to survive. Adaptation of neoplastic cells is a crucial driving force in the progression towards a more aggressive and resistant tumor phenotype [2,3,4,5]. Key mediators in this phenomenon are the hypoxia-inducible factors (HIFs), able to modulate the expression of genes involved in almost all key step of tumor progression as survival, angiogenesis, metabolic reprogramming, immortalization, EMT, stem cell maintenance, resistance to radiation and chemotherapy, invasion and metastasis .
Even if the presence of hypoxic areas is common in all breast lesions, no data clearly correlate low oxygenation with the acquisition of malignant features by non-invasive cells, particularly by cells from ductal carcinoma in situ (DCIS), that constitutes the 20–25% of newly diagnosed breast cancers in industrialized countries [7, 8].
In recent years, retinoids, active metabolites of vitamin A, have been proven promising agents in the management of solid tumors, exerting their function on cell growth and regulating mitochondrial permeability, death receptors, ubiquitination, and oxygen reactive species [9, 10]. The biological activity of retinoids is primarily mediated by activation of nuclear retinoid-receptors, ligand-activated transcription factors, which are grouped into RARs and RXRs families . All-trans retinoic acid (ATRA), a well-known anti-leukemic drug [11, 12], is the only example of a clinically useful cyto-differentiating agent in treatment of some solid tumors, resulting less toxic and more specific than conventional chemotherapy [13, 14]. In cells from invasive breast tumors ATRA acts preferentially by decreasing proliferation and increasing differentiation and apoptosis, mainly through its nuclear RARα [15, 16]. Moreover, the pleotropic effects of ATRA in breast cancer cells were also correlated to non-genomic and multi-layered pathways also aimed to target the cancer stem cells-like population [17, 18].
Among the molecules up-modulated by ATRA in leukemic cells, the beta 2 isoform of the phosphoinositide-dependent phospholipase C (PLC-β2) is ectopically expressed in primary invasive breast tumors in which it strongly correlates with malignancy and poor prognosis . PLC-β2 is also expressed in invasive breast tumor-derived cell lines with different phenotypes, in which it sustains invasion capability . In low invasive breast tumor derived cells, PLC-β2 is down-modulated by low oxygen availability and its over-expression prevents the hypoxia-induced increase of cells showing high surface levels of the cancer stem cell marker CD133 .
Aim of this study was to assess if low oxygen availability induces malignant properties in cells derived from DCIS and to establish whether ATRA, possibly through up-modulation of PLC-β2, may counteract the impact of hypoxia in non-invasive breast cancer cells.
All reagents were from Sigma (St Louis, MO) unless otherwise indicated.
Cell culture and reagents
The breast cancer-derived cell line MCF10DCIS, kindly provided and characterized by Dr. Macpherson (Beatson Institute for Cancer Research, Glasgow, UK), was cultured in Advanced DMEM/F12 medium (Gibco Laboratories, Grand Island, NY), 1% L-Glutamine, 5% horse serum (HS, Gibco Laboratories) and 1% penicillin-streptomycin solution (Gibco Laboratories) and grown at 37 °C in a humidified atmosphere of 5% CO2 in air. Sub-confluent cells were counted daily, maintained between 2 × 105/cm2 and 3 × 105/cm2 and cell morphology was evaluated using an inverted phase-contrast microscope (Nikon, Melville, NY).
Exposure of cell cultures to hypoxia (1% O2) was performed in Forma™ Series II Water Jacketed CO2 Incubator (Thermo Fisher Scientific Inc., Waltham, MA).
Increasing concentrations of ATRA (0.1 μM, 1 μM, 10 μM) dissolved in DMSO were administered to MCF10DCIS cells grown at both normoxia and hypoxia for 4 days.
Cells in all experimental conditions were daily counted by means of a hemocytometer in the presence of trypan blue, in order to determine the number of viable cells.
The morphology of cells under the different experimental conditions was analyzed with an inverted phase-contrast microscope (Nikon Eclipse TE2000-E, Nikon S.p.a., Florence, I). Cell images were acquired using the ACT-1 software for the DXM1200F digital camera (Nikon) and analyzed with the ImageJ software (http://rsb.info.nih.gov/ij/), as previously reported . For each experimental condition, 3 different areas containing at least 100 cells were analyzed and cells were defined “elongated” when their longest axis was at least 2 times larger than their shortest axis.
Immunochemical and immunocytochemical analysis
Total cell lysates were separated on 7.5% polyacrylamide denaturating gels and blotted to nitrocellulose membranes (GE Healthcare Life Science, Little Chalfont, UK). The membranes were reacted with antibodies directed against HIF-1α, CAIX, RARα, Vimentin, E-Cadherina and SLUG (Santa Cruz Biotechnology) and β-tubulin (Sigma), as previously reported . The immunocomplexes were detected by chemiluminescence using the ECL system (Perkin-Elmer, Boston, MA), according to the manufacturer’s instructions. The chemiluminescence derived bands were acquired with an ImageQuantTM LAS 4000 biomolecular imager (GE Healthcare Life Science) and the densitometrical analysis was performed by means of Image Quant TL software (GE Healthcare Life Science).
Immunocytochemical analysis of PLC-β2, HIF-1α and β-catenin was performed essentially as previously described . In particular, cells grown onto glass slides under different experimental conditions were fixed with freshly prepared 4% paraformaldehyde, washed once in PBS, incubated with the primary antibodies (Santa Cruz Biotechnology) for 3 h in NET gel at room temperature and then reacted with a FITC-conjugated secondary antibody diluted in NET gel. Fluorescent samples were analyzed with a Nikon Eclipse TE2000-E microscope (Nikon), acquiring cell images by the ACT-1 software for a DXM1200F digital camera (Nikon). To measure flurescence staining, digitized images were analyzed with the ImageJ software, following the manufacturer’s instructions (http://rsb.info.nih.gov/ij/).
Real-time assays of cell migration and invasion
Cells were subjected to migration and invasion assays under normoxic and hypoxic culture conditions by means of the xCELLigence RTCA system (Real-Time Cell Analyzer System, Acea Biosciences Inc., San Diego, CA), developed to monitor cell events in real time, without incorporation of dyes, by measuring electrical impedance, essentially as previously reported . For migration assays, 4 × 105 cells ∕ well were seeded onto the top chambers of CIM-16 plates and the bottom chambers were filled with medium containing 5% FBS as chemoattractant. For analysis of invasiveness, the upper side of the upper chambers were covered with a layer of diluted Matrigel (BD Biosciences, 1:20 and 1:40) and the bottom chambers were filled with medium containing 10% FBS. For both migration and invasion assays, each condition was performed in quadruplicate and the signal detection was programmed every 15 min for a total of 24 h. Impedance values were expressed as a dimensionless parameter termed Cell Index (CI). The rate of cell migration and invasion was also determined by calculating the slope, that describes the steepness, incline, gradient, and changing rate of the Cell Index curves over time.
To measure migration and invasion under hypoxia, all the procedures described above were performed by allocating the RTCA station inside the incubator, in which the oxygen concentration was 1% for the entire duration of the experiment.
Cytofluorimetrical evaluation of CD133 expression
CD133 surface expression was evaluated by flow cytometry by direct staining of cells with a phycoerythrin (PE)-conjugated anti-CD133/2 monoclonal antibody (293C3, Miltenyi Biotec, Bologna, I), following a previously reported procedure [21, 23]. In particular, 5 × 105 cells, under the different experimental conditions, were incubated with 10 μl of CD133-PE antibody in 100 μl of PBS for 10 min at 4 °C in the dark. After washing with cold PBS, a solution containing 7-amino-actinomycin D (BD Biosciences, San Josè, CA) was added to the samples to identify dead cells to be excluded from the analysis, following manufacturer’s protocol. Non-specific fluorescence was assessed by using an isotype-matched control, Mouse IgG1-PE (Immunotech, Coulter Company, Marseille, F). All samples were analyzed by a FACS Calibur flow cytometer (BD Biosciences) with CellQuest Pro 6.0 software (BD Biosciences). Data collected from 10,000 cells are shown as a percentage of positive cells or as Mean Fluorescence Intensity (MFI) values.
Quantitative analysis of PLC-β2 mRNA and down-modulation of PLC-β2 expression
High-quality total RNA from cells under different experimental conditions was extracted with RNeasy® Micro Kit (Qiagen S.P.A., Milan, I), as previously reported . The first-strand cDNA was synthesized from RNA using the ImProm-II™ Reverse Transcription System kit (Promega, Madison, WI). The cDNA synthesis was carried out by using the GeneAmp® PCR System 2700 thermal cycler (Thermo Fisher Scientific). The obtained cDNAs were employed as template for quantitative Real-Time PCR for PLC-β2 measurement using the TaqMan® Gene Expression Assay (Thermo Fisher Scientific). Thermal cycling and fluorescence detection were performed according to the manufacturer′s instruction, using a Bio-Rad CFX96™ sequence detection system (Bio-Rad Laboratories, Hercules, CA) and the data were analyzed by using a dedicated software (Bio-Rad). Quantification of mRNA expression was calculated by the 2-∆CT method and normalized to the expression of RPL13A mRNA levels.
The down-modulation of PLC-β2 expression was performed by silencing the protein with a pool of 3 target-specific 20-25 nt siRNAs designed by Santa Cruz Biotechnology (Santa Cruz) and transfection was conducted with 1 mg/ml Lipofectamine 2000 (Invitrogen), as previously reported . As a control of transfection efficiency, a non-silencing fluorescein-labeled duplex siRNA, purchased from Qiagen, was used. Transfected cells were incubated at 37 °C in a 5% CO2 atmosphere in growing medium under normoxic and hypoxic conditions prior to RNA extraction and cellular assays.
Statistical analysis was performed by using the non-parametric Mann-Whitney U test for independent samples (SPSS Inc., Chicago, IL). Two-sided tests were used and P-values < 0.05 were considered statistically significant.
Hypoxia induces malignant properties in DCIS-derived cells
In order to assess the role of low oxygen availability in breast cancer progression, the effects of hypoxia were investigated in the MCF10DCIS cell line, the only well- established model of DCIS . MCF10DCIS were cultured at normoxia (21% oxygen) or moderate hypoxia (1% oxygen) and evaluated for their malignant properties. As shown in Fig. 1a, low oxygen availability had no effect on cell growth up to 96 h while longer exposure time induced a significant decrease of the number of viable cells. The evaluation of HIF-1α indicated a time dependent accumulation of this master regulator of hypoxia-induced gene transcription (Fig. 1b, c). Because, among the molecules up-regulated by hypoxia through the activity of HIF-1α, the cell surface protein carbonic anhydrase IX (CAIX) is one of the more specific for non-invasive breast cancer cells , this protein was evaluated in MCF10DCIS cells cultured under hypoxia. The strong amount of CAIX revealed at all the explored times (Fig. 1b, c) confirmed that our experimental model of low oxygen availability is effective in inducing the hypoxia-related intracellular signalling in MCF10DCIS. On the basis of these preliminary experiments, 96 h have been chosen for evaluation of the effects of low oxygen availability on malignancy of MCF10DCIS.
Phase contrast analysis of cell morphology revealed that 96 h of culture under hypoxic conditions substantially modified the cell shape, with the appearance of cytoplasmic elongations and the acquisition of a spindle-like phenotype (Fig. 2a), suggestive of increased motility.
The ability of low oxygen availability to induce loss of cell-to-cell adhesion, one of the first and crucial stages of malignant progression, was investigated in MCF10DCIS cells cultured under hypoxia by evaluating the canonical EMT markers. As shown in Fig. 2b, MCF10DCIS cells express both proteins and 96 h of culture under low oxygen induced a significant reduction of the epithelial marker E-cadherin and a strong increase of the mesenchymal marker Vimentin.
To assess if the hypoxia-related modifications of morphology and of EMT markers are sufficient to increase migration and/or invasion of MCF10DCIS cells, the Real-Time Cell Analyzer system was used, allowing to demonstrate that 96 h of hypoxia induced a significant increase of the migration capability but had no effect on the invasive properties of this cell line (Fig. 2c).
As it is known that hypoxia may induce the appearance of cells expressing CD133 in breast tumors [23, 26], this cancer stem cell marker was evaluated in MCF10DCIS cultured under low oxygen, showing that the small sub-population of CD133 positive cells detectd at normoxia significantly increased after 96 h of growth under low oxygen availability (Fig. 2d).
All-trans retinoic acid (ATRA) counteracts the effects of hypoxia on DCIS- derived cells
At variance with invasive breast cancer derived cells, in which the possible use of ATRA and other retinoids were described to be dependent on tumor phenotypes , no data are available on the effects of these drugs in non-invasive breast tumors. Since the rational for the use of retinoids in breast cancer cells requires responsiveness of tumor cells, we firstly established if MCF10DCIS cells are susceptible to ATRA at concentrations commonly used in invasive breast tumor-derived cells. The immunochemical analysis revealed that MCF10DCIS cells express RARα, that significantly increased in a concentration and time related manner as a consequence of ATRA administration (Fig. 3a, b). Following the procedure employed with invasive breast tumor derived cells , cell growth was daily monitored, showing that 0.1 μM ATRA was ineffective while 1 μM and 10 μM induced a similar significant decrease of cell proliferation (Fig. 3c), definitely assessing the sensitivity of MCF10DCIS cells to this retinoid.
On the basis of the known role of ATRA in attenuating hypoxia-induced injury in non-trasformed cells , its possible role in counteracting the effect of low oxygen availability in non-invasive breast cancer cells was investigated. MCF10DCIS cells were then cultured under moderate hypoxia for 96 h in the presence of 1 μM ATRA, revealing an agonist induced decrease of cell growth similar to that observed under normoxia (Fig. 4a). On the basis of the reported interconnection between HIF-1α and retinoid receptors , the effects of ATRA on HIF-1α (Fig. 4b) and on its target CAIX (Fig. 4c) were evaluated, failing to show significant changes under both normoxia and hypoxia.
Concerning cell morphology, cells grown under hypoxia in the presence of ATRA showed a less elongated shape (Fig. 5a), similar to that of cells cultured in normoxia, suggesting that ATRA counteracts the increased motility induced by low oxygen availability in DCIS derived cells. Accordingly, the Real-Time assay of motility of MCF10DCIS cells under the same experimental conditions demonstrated that ATRA significantly reduces their migratory capability (Fig. 5b).
The immunochemical analysis of the EMT markers revealed that ATRA prevented the effects of hypoxia by inducing a significant increase of E-cadherin and a large decrease of Vimentin (Fig. 6a, b). When a more accurate analysis of the EMT process was performed, we found that, while nor hypoxia neither ATRA affected the expression of β-catenin (Fig. 6a, b), low oxygen availability induced its nuclear accumulation, that was partially inhibited by the administration of the retinoid (Fig. 6c). Accordingly, hypoxia induced the expression of SLUG, that was substantially prevented by ATRA administration (Fig. 6d, e).
Since we have above demonstrated that hypoxia induced an increase of MCF10DCIS cells expressing high levels of CD133, this surface antigen was evaluated in cells treated with ATRA during low oxygen exposure. As reported in Fig. 7, ATRA significantly reduced the percentage of CD133 positive cells, almost completely abrogating the up-modulation of this surface antigen induced by hypoxia.
PLC-β2 mediates the effects of ATRA on CD133 expression in MCF10DCIS cells cultured under hypoxia
We previously demonstrated that PLC-β2, induced by ATRA in APL-derived cells , is down-modulated by low oxygen availability in invasive breast tumor derived cells and that its forced expression reduced the levels of CD133 independently on cell phenotype [21, 23]. Starting from these evidence, a set of experiments was planned to assess the involvement of PLC-β2 in the mechanism by which ATRA counteracts the hypoxia-induced CD133 expression. MCF10DCIS were then cultured for 96 h under low oxygen and both PLC-β2 mRNA and protein amount were evaluated. As shown in Fig. 8a, the mRNA for PLC-β2, quantified by QRT-PCR, significantly decreased after exposure to 1% oxygen. Accordingly, immunocytochemical analysis of cells grown under the same conditions showed a decrease of the protein amount (Fig. 8b). On the other hand, 96 h of 1 μM ATRA induced the expression of PLC-β2 to a significant extent, in terms of mRNA (Fig. 8a) and protein expression (Fig. 8b), in MCF10DCIS cultured in normoxia or under low oxygen.
As determined by flow cytometry, the number of MCF10DCIS cells expressing CD133 at surface level markedly increased as a consequence of the silencing of PLC-β2 during ATRA administration (Fig. 8c), completely abrogating the effects of the retinoid on this surface antigen.
The progression of breast cancer is a very complex and largely unknown phenomenon and seems to depend on various exogenous and endogenous factors [8, 31]. Low oxygen availability, generating a hostile microenvironment in which tumor cells need to activate adaptive mechanisms in order to survive, may have a crucial role in tumor aggressiveness [1, 2, 5]. Accordingly, in breast cancer as in many other solid cancers, low oxygen availability is associated with a clinically aggressive tumor behavior .
Even if a non-obligate precursor, DCIS may be a crucial step in progression to invasive ductal carcinoma . Despite hypoxia was reported to promote a cancer-like phenothype in breast epithelial cells  and a dedifferentiated phenotype in DCIS , no clear correlation between low oxygen availability and malignant progression of non-invasive breast lesions was demonstrated. This study was therefore planned to investigate the role of low oxygenation on malignant properties of MCF10DCIS cells, one of the very few established models of DCIS that, in immunocompromised mice, resulted in rapidly growing lesions that are predominantly high-grade comedo ductal carcinoma in situ .
We demonstrated that 96 h of culture at moderate hypoxia are sufficient to induce the epithelial-to-mesenchymal shift, as MCF10DCIS cells cultured under low oxygen loss their epithelial-like shape in favor of a spindle-like phenotype, suggestive of acquired motility. The resulted higher migration capability is in agreement with previous data showing that hypoxia induced the acquisition of migratory and fibroblastoid-like features by polarized non-motile breast derived cells . The nuclear accumulation of β-catenin and the increased expression of its target SLUG, known to have a crucial role in response of breast tumor cells to hypoxia , allowed to definitely assess that low oxygen availability induces EMT in DCIS derived cells. Since EMT may be involved in progression from in situ to invasive breast tumors , our data confirm that low oxygenation may promote one of the first and most crucial stages of malignant progression in non-invasive breast tumor cells.
The link between hypoxia and cancer stem cells is well documented , and cells with a stem-like phenotype were responsible for initiating metastatic growth in various cancers including breast [38, 39]. Increase in stemness induced by hypoxia was reported also in breast tumor cells and tissues [40, 41], and in breast cancer, like in other solid tumors, the expression of the cancer stem cell marker CD133 is associated with low oxygen availability . We revealed here a significant enlargement of the cell population expressing CD133 at surface level in MCF10DCIS cultured under low oxygen, indicating that, in non-invasive as well as in low invasive breast tumor derived cells , low oxygen availability induces the appearance of cells with a stem-like phenotype.
Also taking into account the limitation of the study due to the two-dimensional cell culture, this bulk of data, proves the ability of low oxygen availability to promote the EMT process and the appearance of a stem-like phenotype in non-invasive cells, suggesting that drugs acting on hypoxia-related events may prevent malignant progression of non-invasive breast lesions.
In order to counteract the effects of hypoxia in non-invasive breast tumor cells, MCF10DCIS cells were treated with ATRA, a well-known anti-leukemic drug that has been demonstrated to exert anti-tumor roles in cells from invasive breast tumors . In particular, ATRA is reported to induce the formation of adherent junctions and the reorganization of tight junctions by activating a RARα-dependent epithelial differentiation program in sensitive breast tumor cells . ATRA was also reported to promote re-differentiation of early transformed breast epithelial cells  and to attenuate hypoxia-induced injury in non-transformed cells . We demonstrated here that the administration of ATRA to MCF10DCIS cells cultured under low oxygen, at concentrations similar to those used with invasive breast tumor-derived cells , prevented the mesenchymal shift induced by hypoxia. In agreement with the anti-tumor activity of ATRA in invasive breast tumor, that includes anti-migratory properties , we demonstrated that this retinoid hamper the increased motility induced by hypoxia in DCIS derived cells. Finally, in the same cell model, we revealed that ATRA almost completely abrogates the effects of hypoxia on CD133 expression. This suggests that, at least in our in vitro model of non-invasive breast cancer, ATRA is efficient in eliminating hypoxia-induced cells with a stem-like phenotype.
At the basis of the controversial role of ATRA in cancer is the complex retinoid signaling pathway, that regulates the expression of hundreds of genes and modulates a wide variety of fundamental biological processes. In breast cancer, the effects of retinoids seem to depend on which retinoic acid (RA)-inducible genes are expressed as well as on non-genomic effects . In order to elucidate the mechanism by means of which ATRA counteracts the effects of hypoxia in non-invasive breast tumor cell, we have considered the signaling activated by this agonist during differentiation of promyelocytic precursor. We found that PLC-β2, induced by ATRA in APL-derived cells , is down-modulated by hypoxia in low invasive breast tumor derived cells . We have also previously demonstrated that PLC-β2 may counteract the expression of CD133 in invasive breast tumor derived cells cultured in normoxia  or hypoxia , allowing to hypothesize a role for this PLC isozyme in mediating the role of ATRA in DCIS-derived cells cultured under hypoxia. Our data revealed that, as in low invasive breast tumor derived cells, PLC-β2 is ectopically expressed in MCF10DCIS and it is significantly down-modulated as a consequence of low oxygen availability. As in leukemic cells, we found that ATRA induces the expression of PLC-β2 in MCF10DCIS cells, substantially counteracting the decrease of the protein induced by low oxygen exposure. Under hypoxia, we proved that PLC-β2 is essential for the role of ATRA in reducing CD133 expression, demonstrating its crucial role in down-modulating this cancer stem cell marker also in non-invasive breast tumor derived cells. Despite the complexity of the retinoid signaling in breast tumors, our results clearly demonstrate that PLC-β2 is a target for ATRA also in breast tumor cells and is part of the mechanism by means of which this agonist inhibits the acquisition of malignant properties by non-invasive breast tumor-derived cells as a consequence of low oxygen availability. Further results to substantiate the acquired evidence could be obtained by performing the assays on additional non-invasive cell lines with different phenotypes once they will be commercially available.
Overall, the reported data establish that hypoxia may have a crucial role in the malignant evolution of non-invasive breast lesions and suggest that the administration of ATRA, a well-known anti-tumor drug in leukemia, may be regarded with interest to prevent potential malignant progression of non-invasive breast tumors with hypoxic areas.
Acute promyelocytic leukemia
All-trans retinoic acid
Ductal carcinoma in situ
- DMEM F/12:
Dulbecco'’s modified Eagle'’s and Ham'’s F-12 media
Fetal bovine serum
Phosphoinositide-dependent phospholipase C β2
Real-Time Cell Analyzer
Small interfering RNAs
Holmquist L, Löfstedt T, Påhlman S. Effect of hypoxia on the tumor phenotype: the neuroblastoma and breast cancer models. Adv Exp Med Biol. 2006;587:179–93.
Dhani N, Fyles A, Hedley D, Milosevic M. The clinical significance of hypoxia in human cancers. Semin Nucl Med. 2015;45:110–21.
Semenza GL. Molecular mechanisms mediating metastasis of hypoxic breast cancer cells. Trends Mol Med. 2012;18:534–54.
Semenza GL. The hypoxic tumor microenvironment: a driving force for breast cancer progression. Biochim Biophys Acta. 2016;1863:382–91.
Rohwer N, Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat. 2011;14:191–201.
Gilkes DM, Semenza GL. Role of hypoxia-inducible factors in breast cancer metastasis. Future Oncol. 2013;9:1623–36.
Mardekian SK, Bombonati A, Palazzo JP. Ductal carcinoma in situ of the breast: the importance of morphologic and molecular interactions. Hum Pathol. 2016;49:114–23.
Carraro DM, Elias EV, Andrade VP. Ductal carcinoma in situ of the breast: morphological and molecular features implicated in progression. Biosci Rep. 2014;34:e00090.
Bushue N, Wan YJY. Retinoid pathway and cancer therapeutics. Adv Drug Deliv Rev. 2010;62:1285–98.
Connolly RM, Nguyen NK, Sukumar S. Molecular pathways: current role and future directions of the retinoic acid pathway in Cancer prevention and treatment. Clin Cancer Res. 2013;19:1651–9.
McCulloch D, Brown C, Iland H. Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives. Onco Targets Ther. 2017;10:1585–601.
Lo-Coco F, Cicconi L, Breccia M. Current standard treatment of adult acute promyelocytic leukaemia. Br J Haematol. 2016;172:841–54.
Alizadeh F, Bolhassani A, Khavari A, Bathaie SZ, Naji T, Bidgoli SA. Retinoids and their biological effects against cancer. Int Immunopharmacol. 2014;18:43–9.
Peinemann F, van Dalen EC, Tushabe DA, Berthold F. Retinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantation. Cochrane Database Syst Rev. 2015;1:CD010685.
Garattini E, Bolis M, Garattini SK, Fratelli M, Centritto F, Paroni G, Gianni' M, Zanetti A, Pagani A, Fisher JN, et al. Retinoids and breast cancer: from basic studies to the clinic and back again. Cancer Treat Rev. 2014;40:739–49.
Zanetti A, Affatato R, Centritto F, Fratelli M, Kurosaki M, Barzago MM, Bolis M, Terao M, Garattini E, Paroni G. All- trans -retinoic acid modulates the plasticity and inhibits the motility of breast Cancer Cells (TGFβ). J Biol Chem. 2015;290:17690–709.
Coyle KM, Maxwell S, Thomas ML, Marcato P. Profiling of the transcriptional response to all-trans retinoic acid in breast cancer cells reveals RARE independent mechanisms of gene expression. Sci Rep. 2017;7:16684.
Wu MJ, Kim MR, Chen YS, Yang JY, Chang CJ. Retinoic acid directs breast cancer cell state changes through regulation of TET2-PKCζ pathway. Oncogene. 2017;36:3193–206.
Bertagnolo V, Benedusi M, Querzoli P, Pedriali M, Magri E, Brugnoli F, Capitani S. PLC-beta2 is highly expressed in breast cancer and is associated with a poor outcome: a study on tissue microarrays. Int J Oncol. 2006;28:863–72.
Bertagnolo V, Benedusi M, Brugnoli F, Lanuti P, Marchisio M, Querzoli P, Capitani S. Phospholipase C-beta 2 promotes mitosis and migration of human breast cancer-derived cells. Carcinogenesis. 2007;28:1638–45.
Brugnoli F, Grassilli S, Al-Qassab Y, Capitani S, Bertagnolo V. PLC-beta2 is modulated by low oxygen availability in breast tumor cells and plays a phenotype dependent role in their hypoxia-related malignant potential. Mol Carcinog. 2016;55:2210–21.
Bertagnolo V, Nika E, Brugnoli F, Bonora M, Grassilli S, Pinton P, Capitani S. Vav1 is a crucial molecule in monocytic/macrophagic differentiation of myeloid leukemia-derived cells. Cell Tissue Res. 2011;345:163–75.
Brugnoli F, Grassilli S, Piazzi M, Palomba M, Nika E, Bavelloni A, Capitani S, Bertagnolo V. In triple negative breast tumor cells , PLC-β2 promotes the conversion of CD133 high to CD133 low phenotype and reduces the CD133-related invasiveness. Mol Cancer. 2013;12:165.
Miller FR, Santner SJ, Tait L, Dawson PJ. MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J Nat Cancer Inst. 2000;92:1185–6.
van Brussel AS, Adams A, Vermeulen JF, Oliveira S, van der Wall E, Mali WP, van Diest PJ, Van Bergen En Henegouwen PM. Molecular imaging with a fluorescent antibody targeting carbonic anhydrase IX can successfully detect hypoxic ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2013;140:263–72.
Currie MJ, Beardsley BE, Harris GC, Gunningham SP, Dachs GU, Dijkstra B, Morrin HR, Wells JE, Robinson BA. Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity. Hum Pathol. 2013;44:402–11.
Centritto F, Paroni G, Bolis M, Garattini SK, Kurosaki M, Barzago MM, Zanetti A, Fisher JN, Scott MF, Pattini L, et al. Cellular and molecular determinants of all-trans retinoic acid sensitivity in breast cancer: luminal phenotype and RARα expression. EMBO Mol Med. 2015;7:950–72.
Xu Y, Gao AM, Ji LJ, Li X, Zhong LL, Li HL, Zheng DH. All-trans retinoic acid attenuates hypoxia-induced injury in NRK52E cells via inhibiting NF-x03BA;B/VEGF and TGF-β2/VEGF pathway. Cell Physiol Biochem. 2016;38:229–36.
Fernández-Martínez AB, Arenas Jiménez MI, Lucio Cazaña FJ. Retinoic acid increases hypoxia-inducible factor-1α through intracrine prostaglandin E(2) signaling in human renal proximal tubular cells HK-2. Biochim Biophys Acta. 2012;1821:672–83.
Bertagnolo V, Marchisio M, Pierpaoli S, Colamussi ML, Brugnoli F, Visani G, Zauli G, Capitani S. Selective up-regulation of phospholipase C-beta2 during granulocytic differentiation of normal and leukemic hematopoietic progenitors. J Leukoc Biol. 2002;71:957–65.
Cowell CF, Weigelt B, Sakr RA, Ng CK, Hicks J, King TA, Reis-Filho JS. Progression from ductal carcinoma in situ to invasive breast cancer: revisited. Mol Oncol. 2013;7:859–69.
Lundgren K, Holm C, Landberg G. Hypoxia and breast cancer: prognostic and therapeutic implications. Cell Mol Life Sci. 2007;64:3233–47.
Vaapil M, Helczynska K, Villadsen R, Petersen OW, Johansson E, Beckman S, Larsson C, Påhlman S, Jögi A. Hypoxic Conditions Induce a Cancer-Like Phenotype in Human Breast Epithelial Cells. PLoS One. 2012;7:e46543.
Helczynska K, Kronblad A, Jögi A, Nilsson E, Beckman S, Landberg G, Påhlman S. Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. Cancer Res. 2003;63:1441–4.
Scherbakov AM, Stefanova LB, Sorokin DV, Semina SE, Berstein LM, Krasil'nikov MA. Snail/beta-catenin signaling protects breast cancer cells from hypoxia attack. Exp Cell Res. 2013;319:3150–9.
Choi Y, Lee HJ, Jang MH, Gwak JM, Lee KS, Kim EJ, Kim HJ, Lee HE, Park SY. Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer. Human Pathol. 2013;44:2581–9.
Mimeault M, Batra SK. Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J Cell Mol Med. 2013;17:30–54.
Velasco-Velázquez MA, Popov VM, Lisanti MP, Pestell RG. The role of breast cancer stem cells in metastasis and therapeutic implications. Am J Pathol. 2011;179:2–11.
Oskarsson T, Batlle E, Massagué J. Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell. 2014;14:306–21.
Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, Clouthier SG, Wicha MS. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A. 2012;109:2784–9.
Daly CS, Flemban A, Shafei M, Conway ME, Qualtrough D, Dean SJ. Hypoxia modulates the stem cell population and induces EMT in the MCF-10A breast epithelial cell line. Oncol Rep. 2018;39:483–90.
Ohnishi S, Maehara O, Nakagawa K, Kameya A, Otaki K, Fujita H, Higashi R, Takagi K, Asaka M, Sakamoto N, et al. Hypoxia-inducible factors activate CD133 promoter through ETS family transcription factors. PLoS One. 2013;8:e66255.
Arisi MF, Starker RA, Addya S, Huang Y, Fernandez SV. All trans-retinoic acid (ATRA) induces re-differentiation of early transformed breast epithelial cells. Int J Oncol. 2014;44:1831–42.
The authors thank Dr. Macpherson (Beatson Institute for Cancer Research, Glasgow, UK) for providing well characterized breast cancer-derived cell line MCF10DCIS.
This work was supported by grants from Italian MIUR (FIRB RBAP10Z7FS_002) to S.C and from University of Ferrara (Italy) to V.B.
Availability of data and materials
All data generated or analyzed during this study are included in this published article [and its supplementary information files].
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Al-Qassab, Y., Grassilli, S., Brugnoli, F. et al. Protective role of all-trans retinoic acid (ATRA) against hypoxia-induced malignant potential of non-invasive breast tumor derived cells. BMC Cancer 18, 1194 (2018). https://doi.org/10.1186/s12885-018-5038-6
- Tumor progression